KANAGAWA, JAPAN, SAN DIEGO, CALIFORNIA – August 9th, 2022
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) and RayzeBio, Inc., (“RayzeBio”), a privately held California-based targeted radiopharmaceutical company today announced the expansion of their strategic partnership, initiated August 4th, 2020, for the discovery and development of peptide-radioisotope (RI) conjugates for use as radiopharmaceutical therapeutics. Under the expansion the companies have agreed to the following:
- Extension of the research collaboration term to allow for additional peptide-RI conjugate discovery and development programs.
- RayzeBio grants PeptiDream an option to attain development and commercialization rights in Japan to the joint peptide-RI programs.
“We are delighted to announce the extension of our strategic partnership with RayzeBio as well as the option to attain Japan development and commercialization rights to the existing peptide-RI programs the companies are working on. With our acquisition of PDRpharma, we now have the ability to develop and commercialize peptide-RI products for the Japan market, and we believe these programs will contribute significant value to our growing peptide-RI product portfolio in Japan.” said Patrick C. Reid PhD, President & CEO of PeptiDream.
“Our collaboration with PeptiDream has led to the discovery of novel peptide binders against first-in-class targets for radiopharmaceuticals. Through this partnership, we can develop and ultimately commercialize innovative drugs for patients with various cancer types.” said Ken Song, M.D., President and CEO of RayzeBio.
About PeptiDream Inc.
PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit www.peptidream.com.
About RayzeBio, Inc.
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com.
Inquiries:
PeptiDream Inc.
Contact: Yuko Okimoto, IR & Public Affairs
Email: y-okimoto@peptidream.com
RayzeBio, Inc.
Contact: Arvind Kush
Email: info@rayzebio.com
